ADAG

Adagene
ADAG

$2.81
2.6%
 

About: Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Employees: 174

0
Funds holding %
of 6,689 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

121% more capital invested

Capital invested by funds: $15.5M [Q4 2023] → $34.3M (+$18.8M) [Q1 2024]

55% more funds holding

Funds holding: 11 [Q4 2023] → 17 (+6) [Q1 2024]

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

9.45% more ownership

Funds ownership: 13.02% [Q4 2023] → 22.47% (+9.45%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

Research analyst outlook

We haven’t received any recent analyst ratings for ADAG.

Financial journalist opinion